- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04072796
Neurogenic Bladder and Quality of Life in Patients With Stroke
The Effects of Stroke Related Neurogenic Bladder on The Quality of Life: A Study of Turkish Population
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Neurogenic bladder after stroke is a commonly encountered medical condition which slows down the recovery process and exacerbates the functional status of the patient. The neurogenic bladder may possibly affect the quality of life of patients with stroke.
Objectives: The aim of this study is to investigate the relationship between the quality of life and the neurogenic bladder in Turkish stroke survivors.
Methods: 71 patients with stroke were included in the study. Patients were divided into two groups: the First group consisted of patients with neurogenic bladder and the Second group consisted of patients without neurogenic bladder. Short Form-36 (SF-36), Barthel Index (BI), Functional Ambulation Category (FAC), Mini-Mental Test (MMT) and Beck Depression Inventory (BDI) questionnaires were applied to both groups for clinical evaluations.
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
-
Istanbul, Truthahn, 34186
- Istanbul Physical Medicine and Rehabilitation Training and Research Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Hemorrhagic or ischemic stroke
- No previous stroke history
- Disease duration > 6 months
Exclusion Criteria:
- Patients with different stroke etiologies other than cerebrovascular events (such as traumatic and tumoral pathologies)
- Previous multiple stroke history
- Pre-stroke urinary complaints
- Previous urogenital surgery history
- Spinal Cord Injury (SCI)
- Prostate volume of > 35ml documented with urinary ultrasonography
- Bladder outlet obstruction
- Poorly controlled Diabetes Mellitus (DM)
- Concomitant neurological diseases such as Multiple Sclerosis and Parkinson's Disease
- Anticholinergic, alpha agonist-antagonist drug use
- Sensory and global aphasia
- Severe communication impairment
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Case group
Case group reported urinary complaints
|
Short Form-36 (SF-36), Barthel Index (BI), Functional Ambulation Category (FAC), Mini-Mental Test (MMT) and Beck Depression Inventory (BDI) questionnaires
|
|
Control group
Control group did not have any urinary complaints.
|
Short Form-36 (SF-36), Barthel Index (BI), Functional Ambulation Category (FAC), Mini-Mental Test (MMT) and Beck Depression Inventory (BDI) questionnaires
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Short Form-36 (SF-36)
Zeitfenster: 15 minutes
|
Short Form-36 (SF-36) was used to evaluate the quality of life of the patients.
The form consists of 36 items, which measure 8 dimensions.
These include (1) Physical function, (2) Social function, (3) Pain, (4) Energy/vitality, (5) Role limitation due to emotional problems , (6) Role limitation due to physical health problems, (7) Mental health and (8) General perception of health.
Each subscale is evaluated between 0-100 points.
A higher score indicates the better health.
|
15 minutes
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Beck Depression Inventory
Zeitfenster: 15 minutes
|
Beck Depression Inventory was used to assess depressive signs.
The scale consists of 21 items and the items are ordered from mild to severe.
Evaluation is performed in a range of 0-63 points.
The lower score indicates the better psychological profile.
|
15 minutes
|
|
Mini Mental Test (MMT)
Zeitfenster: 15 minutes
|
Mini Mental Test (MMT) was used to evaluate the extent of cognitive impairment.
MMT is divided into 5 main categories: orientation (10 points), memory (3 points), attention and calculation (5 points), recalling (3 points) and language (9 points).
Total points is 30.
Total score between 0-9 points is considered as severe cognitive impairment.
Total score between 10-19 points is considered as moderate cognitive impairment.
Total score between 20-23 points is considered as mild cognitive impairment.
Total score between 24-30 points is considered as normal.
|
15 minutes
|
|
Brunnstrom scale
Zeitfenster: 15 minute
|
Brunnstrom scale is used to evaluate separately upper extremity, lower extremity or hand functions.
Six stages are defined.
Stage 1: No active movement, Stage 2: Mild spasticity, weak flexor-extensor synergy patterns, Stage 3: Marked spasticity, synergy patterns are evident, Stage 4: Some isolated movements other than synergy patterns can be seen, Stage 5: Decreased spasticity, most muscle activities are isolated, Stage 6: Phasic and well-coordinated isolated movements are performed.
A higher point indicates the better status.
|
15 minute
|
|
Functional Ambulation Category
Zeitfenster: 15 minute
|
Functional Ambulation Category (FAC) was used to evaluate the functional status.
FAC assesses human support for ambulation rather than assistive devices.
FAC 0: nonfunctional ambulation, FAC 1: Ambulator- dependent for physical assistance level II FAC 2: Ambulator- dependent for physical assistance level I, FAC 3: Ambulator-dependent for supervision FAC 4: Ambulator-independent level surfaces only FAC 5: Ambulator-independent.
A higher score indicates the better status.
|
15 minute
|
|
Barthel Index (BI)
Zeitfenster: 15 minute
|
Barthel Index (BI) evaluates functional independence in term of daily living activity.
Total score is 100 points.
A higher point indicates better functional status.
|
15 minute
|
Mitarbeiter und Ermittler
Ermittler
- Studienstuhl: Kadriye Önes, Prof, Istanbul Physical Medicine Rehabilitation Training and Research Hospital
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Milsom I, Kaplan SA, Coyne KS, Sexton CC, Kopp ZS. Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology. 2012 Jul;80(1):90-6. doi: 10.1016/j.urology.2012.04.004.
- Panfili Z, Metcalf M, Griebling TL. Contemporary Evaluation and Treatment of Poststroke Lower Urinary Tract Dysfunction. Urol Clin North Am. 2017 Aug;44(3):403-414. doi: 10.1016/j.ucl.2017.04.007.
- Kim KJ, Heo M, Chun IA, Jun HJ; PhDc; Lee JS, Jegal H, Yang YS. The relationship between stroke and quality of life in Korean adults: based on the 2010 Korean community health survey. J Phys Ther Sci. 2015 Jan;27(1):309-12. doi: 10.1589/jpts.27.309. Epub 2015 Jan 9.
- Best KL, Ethans K, Craven BC, Noreau L, Hitzig SL. Identifying and classifying quality of life tools for neurogenic bladder function after spinal cord injury: A systematic review. J Spinal Cord Med. 2017 Sep;40(5):505-529. doi: 10.1080/10790268.2016.1226700. Epub 2016 Oct 13.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- TURKEYPMR
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .